Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Notes Payables (2020)

Elicio Therapeutics filings provide 1 years of Notes Payables readings, the most recent being $51.2 million for Q4 2020.

  • On a quarterly basis, Notes Payables changed N/A to $51.2 million in Q4 2020 year-over-year; TTM through Dec 2020 was $51.2 million, a N/A change, with the full-year FY2020 number at $51.2 million, changed N/A from a year prior.
  • Notes Payables hit $51.2 million in Q4 2020 for Elicio Therapeutics.
  • In the past five years, Notes Payables ranged from a high of $51.2 million in Q4 2020 to a low of $51.2 million in Q4 2020.